- Open Access
Reduced beta2-glycoprotein I protects macrophages from ox-LDL-induced foam cell formation and cell apoptosis
- Wei-Lin Wang†1,
- Zhen-Xing Meng†1,
- Sai-Jun Zhou1,
- Chun-Jun Li1,
- Rui Chen1,
- Lin Lv1,
- Ze-Jun Ma1,
- De-Min Yu1Email author and
- Pei Yu1Email author
© Wang et al.; licensee BioMed Central Ltd. 2013
- Received: 10 August 2013
- Accepted: 11 November 2013
- Published: 16 November 2013
Reduced beta2-glycoprotein I (beta2-GPI) is a free thiol-containing form of beta2-GPI that displays a powerful effect in protecting endothelial cells from oxidative stress-induced cell death. The present study aims to investigate the effect of beta2-GPI or reduced beta2-GPI on ox-LDL-induced foam cell formation and on cell apoptosis and to determine the possible mechanisms.
The RAW264.7 macrophage cell line was selected as the experimental material. Oil red O staining and cholesterol measurement were used to detect cholesterol accumulation qualitatively and quantitatively, respectively. Flow cytometry was used to detect cell apoptosis. Real-time quantitative PCR was used to detect the mRNA expression of the main proteins that are associated with the transport of cholesterol, such as CD36, SRB1, ABCA1 and ABCG1. Western blot analysis was used to detect the protein expression of certain apoptosis-related proteins, such as caspase-9, caspase-3, p38 MAPK/p-p38 MAPK and JNK/p-JNK.
Beta2-GPI or reduced beta2-GPI decreased ox-LDL-induced cholesterol accumulation (96.45 ± 8.51 μg/mg protein vs. 114.35 ± 10.38 μg/mg protein, p < 0.05;74.44 ± 5.27 μg/mg protein vs. 114.35 ± 10.38 μg/mg protein, p < 0.01) and cell apoptosis (30.00 ± 5.10% vs. 38.70 ± 7.76%, p < 0.05; 20.66 ± 2.50% vs. 38.70 ± 7.76%, p < 0.01), and there are significant differences between beta2-GPI and reduced beta2-GPI (p < 0.05). Reduced beta2-GPI decreased the ox-LDL-induced expression of CD36 mRNA and ABCA1 mRNA (p < 0.05), as well as CD36, cleaved caspase-9, cleaved caspase-3, p-p38 MAPK and p-JNK proteins (p < 0.05 or p < 0.01). Beta2-GPI did not significantly decrease the expression of ABCA1 mRNA and the p-p38 MAPK protein.
Both beta2-GPI and reduced beta2-GPI inhibit ox-LDL-induced foam cell formation and cell apoptosis, and the latter exhibits a stronger inhibition effect. Both of these glycoproteins reduce the lipid intake of macrophages by downregulating CD36 as well as protein expression. Reduced beta2-GPI inhibits cell apoptosis by reducing the ox-LDL-induced phosphorylation of p38 MAPK and JNK, and the amount of cleaved caspase-3 and caspase-9. Beta2-GPI does not inhibit the ox-LDL-induced phosphorylation of p38 MAPK.
- Reduced beta2-glycoprotein I
- Beta2-glycoprotein I
- Foam cell
Foam cells are the characteristic pathological cells in atherosclerotic plaques. The most important reason for foam cell formation is cholesterol accumulation, particularly ox-LDL . A variety of proteins are involved in cholesterol accumulation. ATP-binding cassette transporter A1 (ABCA1) and G1 (ABCG1) are both important outflow pathways for lipids in macrophages [2, 3]. The scavenger receptor CD36 is involved in the intake of ox-LDL . In CD36 knockout mice, the capacities of ox-LDL intake and foam cell formation were both significantly reduced . Another scavenger receptor, SRB1, mediates the outflow of cholesterol and inhibits the progress of atherosclerosis .
Beta2-glycoprotein I (beta2-GPI) is the main autoantigen for antiphospholipid syndrome, and its molecular weight is approximately 50 kDa, with a circulating concentration of approximately 4 μmol/L in human plasma . Its physiological function remains unclear. Beta2-GPI is composed of five complementary control protein modules, named domain I to domain V, and domain V contains the binding site for negatively charged phospholipids . In the crystal structure of beta2-GPI, a certain disulphide bond is formed between Cys288 and Cys326 of domain V, which is exposed on the surface of this protein [8, 9]. This disulphide bond could be opened by thioredoxin-1 (TRX-1), which resulted in the formation of two free thiols. This form of beta2-GPI is called reduced beta2-GPI [10, 11].
Beta2-GPI is closely associated with atherosclerosis. George et al. proved the presence of beta2-GPI in atherosclerotic plaques . Lin et al. found beta2-GPI could not only inhibit the translocation of cholesterol from extracellular pools to macrophages but also prevent NO-induced apoptosis in vascular cells [13, 14]. Reduced beta2-GPI was recently found to be a protective factor against oxidative stress-induced endothelial cell death , which reminded us of its potential effect against oxidative stress. Our preliminary experiments indicated that beta2-GPI or reduced beta2-GPI alone inhibits foam cell formation from U937 human macrophages. The present study aims to investigate the effect of beta2-GPI or reduced beta2-GPI on ox-LDL-induced foam cell formation and cell apoptosis and to determine the possible mechanisms of these effects.
Results of Oil red O staining
Cholesterol content in macrophages
Results of flow cytometry
Western blot results
The RAW264.7 cell line was established from the ascites of a tumour that was induced in a male mouse by the intraperitoneal injection of Abselon Leukaemia Virus (ATCC Number: TIB-71). RAW264.7 macrophages are easy to culture and have strong adhesion and phagocytosis abilities, which cause its wide use in studies of the pathways of foam cell formation [15, 16]. There are two important biological characteristics of foam cells. On one hand, the lipid content in the cytoplasm increases significantly, and lipids are gathered into droplets, which are primarily arranged around the inside surface of the cytomembrane; on the other hand, there is a significant increase in the content of total intracellular cholesterol, and the cholesteryl ester content is over 50% of the total intracellular cholesterol . In the present study, macrophages meet both typical characteristics of foam cells after incubation with 75 mg/L of ox-LDL for 24 h.
To determine the concentration of beta2-GPI and reduced beta2-GPI, we set a concentration gradient (50, 100, 150, 200 μmmol/L) in the preliminary experiment and detected the intracellular total cholesterol. Results revealed that beta2-GPI or reduced beta2-GPI alone inhibited ox-LDL-induced cholesterol influx in a dose-dependent fashion. Results showed a statistical significance using the concentration of 100 μmmol/L beta2-GPI or reduced beta2-GPI. Synthesizes related references [13, 14, 18, 19] and our preliminary experiment, the concentration of 100 μmmol/L was selected for the mechanism study.
Our study demonstrates for the first time that both beta2-GPI and reduced beta2-GPI inhibit ox-LDL-induced foam cell formation and cell apoptosis in vitro, and the latter demonstrates a stronger inhibition effect. Both of these glycoproteins reduce the lipid intake of macrophages by downregulating CD36 mRNA as well as protein expression. Reduced beta2-GPI inhibits cell apoptosis by reducing the ox-LDL-induced phosphorylation of p38 MAPK and JNK, as well as the amount of activated caspase-3 and caspase-9. Beta2-GPI does not inhibit the ox-LDL-induced phosphorylation of p38 MAPK.
Beta2-GPI could combine with atherosclerosis factors, such as ox-LDL, CRP and Lp(alpha), to form corresponding stable complexes [20–23]. Ox-LDL/beta2-GPI complexes were found in patients that suffer autoimmune diseases , diabetes , etc. Autoantibodies further combined with beta2-GPI in the complexes to form ox-LDL/beta2-GPI/autoantibody complexes (actually antigen/antibody complexes), which could be phagocytised by macrophages, and actually increased ox-LDL intake and foam cell formation [20, 24, 26]. However, our study revealed that beta2-GPI inhibited ox-LDL intake and foam cell formation in vitro. One possible reason for this result is that there are no autoantibodies in vitro. Thus, beta2-GPI binds with ox-LDL; however, the complexes could not be phagocytised by macrophages. In addition, our study found that beta2-GPI inhibited the ox-LDL-induced expression of CD36 mRNA. Both of these reasons contribute to the decrease in ox-LDL intake and foam cell formation.
Reduced beta2-GPI was first discovered by Ioannou Y et al. in 2010 . Both beta2-GPI (actually oxidised form) and reduced beta2-GPI have recently been found in human serum. Moreover, the proportion of reduced beta2-GPI is significantly lower in the antiphospholipid syndrome group than that in healthy individuals , which suggests that reduced beta2-GPI may play a protective role in our bodies. The reduced form of beta2-GPI is generated when the functional disulphide (Cys288-Cys326) is opened, and this change results in some functional changes [10, 27]. Reduced beta2-GPI was recently found to protect EAhy926 (human vascular endothelial cells) from oxidative stress-induced endothelial cell damage  and to display increased binding to von Willebrand factor (vWF) than non-reduced beta-GPI in vitro .
At present, no studies have reported the correlation between reduced beta2-GPI and atherosclerosis. Our study first discovered that reduced beta2-GPI inhibited ox-LDL-induced cholesterol accumulation in macrophages by inhibiting CD36 expression. However, reduced beta2-GPI simultaneously inhibited ABCA1 expression, which is a protein that decreases cholesterol accumulation in macrophages. Because the net result of these changes is the reduction of foam cell formation, it is proposed that there are also other mechanisms in addition to the decrease of CD36 expression that are responsible for the cholesterol efflux that is induced by reduced beta2-GPI.
Both macrophages and smooth muscle cells undergo apoptosis in atherosclerotic plaques . Macrophage apoptosis promotes the development of the necrotic core, which is a key factor in rendering plaques vulnerable to disruption and in acute luminal thrombosis . Both p38 MAPK and JNK signalling pathways play an important role in cell apoptosis [31, 32]. Caspase-9 and caspase-3 are key proteins in apoptotic pathways . Our study proved that reduced beta2-GPI inhibited the ox-LDL-induced phosphorylation of p38 MAPK and JNK, as well as the amount of activated caspase-9 and caspase-3, thus inhibiting the apoptosis of macrophage-derived foam cells.
Reduced beta2-GPI provides a new direction for the study of beta2-GPI. Currently, the function of reduced beta2-GPI has been poorly understood. Further studies should be performed to investigate this protein’s physiological and pathological roles and to lay the foundation for further clarify related diseases, such as autoimmune diseases and atherosclerosis, as well as biological processes, such as coagulation and oxidative stress. Reduced beta2-GPI may offer a new target for the diagnosis and treatment of certain diseases in the future.
Both beta2-GPI and reduced beta2-GPI inhibit ox-LDL-induced foam cell formation and cell apoptosis, and the latter exhibits a stronger inhibition effect. Both of these glycoproteins reduce the lipid intake of macrophages by downregulating CD36 mRNA as well as protein expression. Reduced beta2-GPI inhibits cell apoptosis by reducing the ox-LDL-induced phosphorylation of p38 MAPK and JNK, as well as the amount of cleaved caspase-3 and caspase-9. Beta2-GPI does not inhibit the ox-LDL-induced phosphorylation of p38 MAPK.
Materials and regents
The RAW264.7 macrophage cell line was purchased from the American Type Culture Collection (ATCC number: TIB-71). Dulbecco’s modified Eagle Medium (DMEM), fetal bovine serum and ox-LDL were purchased from Beijing Solarbio Science & Technology Co., Ltd. (Beijing, China). Oil red O and hematoxylin were purchased from Sigma. An annexin V-FITC apoptosis detection kit was purchased from Nanjing KeyGEN Biotech. Co., Ltd. (Nanjing, China). The TRIzol reagent was purchased from Invitrogen (Carlsbad, America). A Reverse Transcription Kit and SYBR ® Premix Ex TaqTM DNA polymerase were purchased from TaKaRa Bio. Inc. (Otsu, Japan). Rabbit anti-mouse monoclonal antibodies to p38 MAPK, p-p38 MAPK, JNK and p-JNK were purchased from Cell Signaling Technology, Inc. (Boston, America). Rabbit anti-mouse monoclonal antibodies to cleaved caspase-3 and cleaved caspase-9 were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, America). Horseradish peroxidase-labelled goat anti-rabbit IgG was purchased from Beijing ComWin Biotech Co., Ltd. (Beijing, China).
Purification of beta2-GPI
Beta2-GPI was purified from normal human plasma by methods that were described previously . Plasma beta2-GPI was precipitated by 3% (v/v) perchloric acid and isolated by heparin-Sepharose affinity chromatography (HiTrap Heparin, GE Healthcare). LC-MS analysis was used to confirm this protein. The purity of beta2-GPI was confirmed by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) on a 10% mini-gel. The SDS-PAGE analysis of the protein sample showed an identical band to that of the standard sample. The BCA method was used to determine the concentration of beta2-GPI.
Preparation of reduced beta2-GPI
Reduced beta2-GPI was prepared by methods that were described previously . Purified beta2-GPI (1 μM) was reduced by TRX-1 (3.5 μM), which was activated by dithiothreitol (DTT, 70 μM). The thiols of reduced beta2-GPI were protected by reduced glutathione. The reduced beta2-GPI was verified using a Western blot and LC-MS analysis. The Western blot analysis showed that the new protein maintained the same immunological activity with beta2-GPI. The LC-MS analysis verified that domain V of the new protein had free thiols.
RAW264.7 cells were cultured in DMEM with 25 mmol/L glucose, which was supplemented with 10% (v/v) fetal bovine serum at 37°C in a humidified atmosphere with 5% CO2. Cells were routinely subcultured when grown to subconfluency (>90% by visual estimate).
Cells were seeded onto 96-well microtitre plates at a density of 2 × 106 cells per well, cultured for 12 h and then serum-starved for another 24 h. Four groups were designed, and cells were incubated for another 24 h in DMEM, which was supplemented with 25 mmol/L glucose, 10% (v/v) fetal bovine serum and the following intervention factors: (a) blank control; (b) 75 μg/mL ox-LDL; (c) 75 μg/mL ox-LDL + 100 μg/mL beta2-GPI; (d) 75 μg/mL ox-LDL + 100 μg/mL reduced beta2-GPI.
Oil red O staining
Cell culture was the same as above. Culture medium was removed, and cells were washed three times with PBS and fixed in formalin for 30 minutes. Fixed cells were rinsed with PBS and then with 60% isopropanol for 5 minutes, and then stained with freshly prepared Oil Red O working solution for 30 min at 60°C. The nuclei were lightly stained with haematoxylin for 5 minutes. Stained cells were rinsed with distilled water, mounted in glycerine jelly, and then observed using an inverted microscope.
High performance liquid chromatography-mass spectrometry (HPLC-MS)
Column: Inertsil ODS column (5 μm, 150 mm × 4.6 mm, purchased from GL Sciences, Tokyo, Japan). Mobile phase: methanol–water (78:22). Flow rate: mL · min-1. Temperature: room temperature. Application volume: 10 μL.
A previous study has described the quantitative determination of cholesterol by the HPLC-MS method . Based on this method, we made some changes according to our situation. Cells were washed once with cold PBS and then sonicated in ice bath for 5 min. The cell lysate was then subpackaged (200 μL every part). In total, 300 μL of freshly prepared 15% alcohol-KOH was added to 200 μL of cell lysate. After 2 hours, 500 μL of hexane:isopropanol solution (4:1, v/v) was added. After 15 min vortex-mixing, the cell lysate was centrifuged at 4000 rpm for 5 min, and the upper organic phase was collected. Residual free cholesterol in the lower aqueous phase was extracted twice as described above. Then, the total clarified supernatants were collected and evaporated to dryness by vacuum centrifugation. Stigmasterol was used as an internal standard. A calibration curve was constructed according to the LC-MS analysis of solutions that contained stigmasterol (10 μg/mL) and serial dilutions of cholesterol. Then, the dry sample was dissolved with a stigmasterol solution (10 μg/mL) and analysed using the LC-MS method. The total protein in the aqueous phase was detected by the BCA method, and the final cholesterol content was determined using the ratio between the cholesterol concentration and the corresponding protein concentration (μg/mg protein). To detect the total cholesterol content, cholesterol esterase was used to hydrolyse cholesterol ester to free cholesterol. The content of cholesterol ester was equal to the difference between total cholesterol and free cholesterol.
Cell culture was the same as above. Cells were digested with trypsin and collected using centrifugation (2000 rpm, 5 min). 500 μL binding buffer was added to cells. Then 5 μL annexin V-FITC and 5 μL propidium iodide were added to the binding buffer. Samples were kept in a dark place for 5–15 mins at room temperature and then flow cytometric analysis was performed. The excitation wavelength was 488 nm. The emission wavelength was 530 nm.
Real-time quantitative PCR
Primers for all tested genes were designed using the Primer 5.0 software and were evaluated using the Oligo 6.0 software. The primer sequences for CD36 were: forward 5'-GAACCACTGCTTTCAAAAACTGG-3, reverse 5'-TGCTGTTCTTTGCCACGTCA-3'; for SRB1: forward 5'-TTTGGAGTGGTAGTAAAAAGGGC-3', reverse 5'-TGACATCAGGGACTCAGAGTAG-3'; for ABCA-1: forward 5'-AGTGATAATCAAAGTCAAAGGCACAC-3'; reverse 5'-AGCAACTTGGCACTAGTAACTCTG-3'; for ABCG1: forward 5'-TTCATCGTCCTGGGCATCTT-3', reverse 5'-CGGATTTTGTATCTGAGGACGAA-3'; for β-actin: forward 5'-TGGAGAAGAGCTATGAGCTGCCTG-3', reverse 5'-GTGCCACCAGACAGCACTGTGTTG-3'.
Total cellular RNA was isolated using the TRIzol reagent according to the manufacturer’s instructions. Final RNA concentrations were determined by OD values at 260 nm, and integrity was verified by ethidium bromide staining of ribosomal 18S and 28S bands on an agarose gel. The A260/A280 ratios were from 1.8-2.0. Total RNA was reverse transcribed into cDNA using a Reverse Transcription Kit. The PCR reaction system was composed of cDNA, primer, SYBR Green Mix and ddH2O. PCR cycling conditions were set as follows: 94°C for 2 min, then 35 cycles at 94°C for 30 sec, 60°C for 30 sec 45, and 72°C for 20 sec. All sample measurements were performed in triplicate. The relative quantification was based on β-actin genes to determine fold-differences in the expression of the target gene. ΔΔC t - method was used for the normalisation procedure. The final result was shown by the ratio of 2 –ΔΔ Ct in the experimental group to that in the control group.
The reaction was terminated by adding 1 mL of cold PBS, which contained 100 μM sodium vanadate. The samples were then placed on ice, washed with ice-cold PBS, and lysed in RIPA lysis buffer for 30 mins. Lysates were clarified by centrifugation at 12000 rpm for 15 min at 4°C, and the protein content in the supernatant was measured with a Micro BCATM Protein Assay Reagent Kit according to the manufacturer’s instructions. Aliquots (30 μg protein per lane) of the total protein were resolved by NuPAGETM 4–12% Bis-Tris Gel and blotted onto a nitrocellulose transfer membrane. The membrane was blocked with 2% BSA in TBST (20 mM Tris–HCl, pH 7.6, 137 mM NaCl and 0.01% Tween-20) for 1 h at RT, followed by incubation with specific primary antibodies (to CD36, p38 MAPK, p-p38 MAPK, JNK and p-JNK, cleaved caspase-3 and cleaved caspase-9). After washing with TBST, the membrane was reprobed with HRP-anti-rabbit IgG (1:1000) in 2% BSA in TBST for 60 min at RT. Radiography was performed using a UVP analytical instrument. β-actin was selected as the internal standard protein.
The data are expressed as the mean ± SEM. Differences between two groups were analysed using Student’s t-test, and differences between multi-groups were analysed using a one-way analysis of variance. When statistically significant differences were found, individual comparisons were made using Tukey’s test. Significance was taken as p < 0.05.
The authors gratefully acknowledge the financial support from the National Natural Science Foundation of China (No. 81070645), the Tianjin Natural Science Fund (No. 10JCYBJC12000), the Science and Technology Fund of the Tianjin Health Bureau (No. 2012KG135), and the Science and Technology Fund of Tianjin Medical University (No. 2009ky25). No conflict of interest exists.
- Shashkin P, Dragulev B, Ley K: Macrophage differentiation to foam cells. Curr Pharm Des. 2005, 11 (23): 3061-3072. 10.2174/1381612054865064View ArticlePubMedGoogle Scholar
- Feng B, Tabas I: ABCA1-mediated cholesterol efflux is defective in free cholesterol-loaded macrophages. Mechanism involves enhanced ABCA1 degradation in a process requiring full NPC1 activity. J Biol Chem. 2002, 277 (45): 43271-43280. 10.1074/jbc.M207532200View ArticlePubMedGoogle Scholar
- Schmitz G, Langmann T, Heimerl S: Role of ABCG1 and other ABCG family members in lipid metabolism. J Lipid Res. 2001, 42 (10): 1513-1520.PubMedGoogle Scholar
- Rahaman SO, Lennon DJ, Febbraio M, Podrez EA, Hazen SL, Silverstein RL: A CD36-dependent signaling cascade is necessary for macrophage foam cell formation. Cell Metab. 2006, 4 (3): 211-221. 10.1016/j.cmet.2006.06.007PubMed CentralView ArticlePubMedGoogle Scholar
- Febbraio M, Abumrad NA, Hajjar DP, Sharma K, Cheng W, Pearce SF, Silverstein RL: A null mutation in murine CD36 reveals an important role in fatty acid and lipoprotein metabolism. J Biol Chem. 1999, 274 (27): 19055-19062. 10.1074/jbc.274.27.19055View ArticlePubMedGoogle Scholar
- Connelly MA, Williams DL: Scavenger receptor BI: a scavenger receptor with a mission to transport high density lipoprotein lipids. Curr Opin Lipidol. 2004, 15 (3): 287-295. 10.1097/00041433-200406000-00008View ArticlePubMedGoogle Scholar
- Giannakopoulos B, Passam F, Rahgozar S, Krilis SA: Current concepts on the pathogenesis of the antiphospholipid syndrome. Blood. 2007, 109 (2): 422-430. 10.1182/blood-2006-04-001206View ArticlePubMedGoogle Scholar
- Bouma B, de Groot PG, van den Elsen JM, Ravelli RB, Schouten A, Simmelink MJ, Derksen RH, Kroon J, Gros P: Adhesion mechanism of human beta(2)-glycoprotein I to phospholipids based on its crystal structure. Embo J. 1999, 18 (19): 5166-5174. 10.1093/emboj/18.19.5166PubMed CentralView ArticlePubMedGoogle Scholar
- Schwarzenbacher R, Zeth K, Diederichs K, Gries A, Kostner GM, Laggner P, Prassl R: Crystal structure of human beta2-glycoprotein I: implications for phospholipid binding and the antiphospholipid syndrome. Embo J. 1999, 18 (22): 6228-6239. 10.1093/emboj/18.22.6228PubMed CentralView ArticlePubMedGoogle Scholar
- Ioannou Y, Zhang JY, Passam FH, Rahgozar S, Qi JC, Giannakopoulos B, Qi M, Yu P, Yu DM, Hogg PJ: Naturally occurring free thiols within beta 2-glycoprotein I in vivo: nitrosylation, redox modification by endothelial cells, and regulation of oxidative stress-induced cell injury. Blood. 2010, 116 (11): 1961-1970. 10.1182/blood-2009-04-215335View ArticlePubMedGoogle Scholar
- Passam FH, Rahgozar S, Qi M, Raftery MJ, Wong JW, Tanaka K, Ioannou Y, Zhang JY, Gemmell R, Qi JC: Beta 2 glycoprotein I is a substrate of thiol oxidoreductases. Blood. 2010, 116 (11): 1995-1997. 10.1182/blood-2010-02-271494View ArticlePubMedGoogle Scholar
- George J, Harats D, Gilburd B, Afek A, Levy Y, Schneiderman J, Barshack I, Kopolovic J, Shoenfeld Y: Immunolocalization of beta2-glycoprotein I (apolipoprotein H) to human atherosclerotic plaques: potential implications for lesion progression. Circulation. 1999, 99 (17): 2227-30. 10.1161/01.CIR.99.17.2227View ArticlePubMedGoogle Scholar
- Lin KY, Pan JP, Yang DL, Huang KT, Chang MS, Ding PY, Chiang AN: Evidence for inhibition of low density lipoprotein oxidation and cholesterol accumulation by apolipoprotein H (beta2-glycoprotein I). Life Sci. 2001, 69 (6): 707-719. 10.1016/S0024-3205(01)01164-XView ArticlePubMedGoogle Scholar
- Lin KY, Wang HH, Lai ST, Pan JP, Chiang AN: beta(2)-glycoprotein I protects J774A.1 macrophages and human coronary artery smooth muscle cells against apoptosis. J Cell Biochem. 2005, 94 (3): 485-496. 10.1002/jcb.20314View ArticlePubMedGoogle Scholar
- Liu Q, Dai Z, Liu Z, Liu X, Tang C, Wang Z, Yi G, Liu L, Jiang Z, Yang Y: Oxidized low-density lipoprotein activates adipophilin through ERK1/2 signal pathway in RAW264.7 cells. Acta Biochim Biophys Sin (Shanghai). 2010, 42 (9): 635-645. 10.1093/abbs/gmq070View ArticleGoogle Scholar
- Yao S, Zong C, Zhang Y, Sang H, Yang M, Jiao P, Fang Y, Yang N, Song G, Qin S: Activating transcription factor 6 mediates oxidized LDL-induced cholesterol accumulation and apoptosis in macrophages by up-regulating CHOP expression. J Atheroscler Thromb. 2013, 20 (1): 94-107. 10.5551/jat.13425View ArticlePubMedGoogle Scholar
- Fogelman AM, Shechter I, Seager J, Hokom M, Child JS, Edwards PA: Malondialdehyde alteration of low density lipoproteins leads to cholesteryl ester accumulation in human monocyte-macrophages. Proc Natl Acad Sci U S A. 1980, 77 (4): 2214-2218. 10.1073/pnas.77.4.2214PubMed CentralView ArticlePubMedGoogle Scholar
- Yu P, Passam FH, Yu DM, Denyer G, Krilis SA: Beta2-glycoprotein I inhibits vascular endothelial growth factor and basic fibroblast growth factor induced angiogenesis through its amino terminal domain. J Thromb Haemost. 2008, 6 (7): 1215-1223. 10.1111/j.1538-7836.2008.03000.xView ArticlePubMedGoogle Scholar
- Chiu WC, Chiou TJ, Chiang AN: beta(2)-Glycoprotein I inhibits endothelial cell migration through the nuclear factor kappaB signalling pathway and endothelial nitric oxide synthase activation. Biochem J. 2012, 445 (1): 125-133. 10.1042/BJ20111383View ArticlePubMedGoogle Scholar
- Lopez LR, Kobayashi K, Matsunami Y, Matsuura E: Immunogenic oxidized low-density lipoprotein/beta2-glycoprotein I complexes in the diagnostic management of atherosclerosis. Clin Rev Allergy Immunol. 2009, 37 (1): 12-19. 10.1007/s12016-008-8096-8View ArticlePubMedGoogle Scholar
- Foteinos G, Xu Q: Immune-mediated mechanisms of endothelial damage in atherosclerosis. Autoimmunity. 2009, 42 (7): 627-633. 10.1080/08916930903002529View ArticlePubMedGoogle Scholar
- Zhang C, Li K, Shi B, Wang X, Liu X, Qin W, Han A, Wang J: Detection of serum beta(2)-GPI-Lp(a) complexes in patients with systemic lupus erythematosus. Clin Chim Acta. 2010, 411 (5–6): 395-399.View ArticlePubMedGoogle Scholar
- Zhang R, Zhou SJ, Li CJ, Wang XN, Tang YZ, Chen R, Lv L, Zhao Q, Xing QL, Yu DM: C-reactive protein/oxidised low-density lipoprotein/beta2-glycoprotein I complex promotes atherosclerosis in diabetic BALB/c mice via p38mitogen-activated protein kinase signal pathway. Lipids Health Dis. 2013, 12: 42- 10.1186/1476-511X-12-42PubMed CentralView ArticlePubMedGoogle Scholar
- Kobayashi K, Kishi M, Atsumi T, Bertolaccini ML, Makino H, Sakairi N, Yamamoto I, Yasuda T, Khamashta MA, Hughes GR: Circulating oxidized LDL forms complexes with beta2-glycoprotein I: implication as an atherogenic autoantigen. J Lipid Res. 2003, 44 (4): 716-726. 10.1194/jlr.M200329-JLR200View ArticlePubMedGoogle Scholar
- Lopez LR, Hurley BL, Simpson DF, Matsuura E: Oxidized low-density lipoprotein/beta2-glycoprotein I complexes and autoantibodies in patients with type 2 diabetes mellitus. Ann N Y Acad Sci. 2005. 1051: 97-103. 10.1196/annals.1361.050View ArticlePubMedGoogle Scholar
- Matsuura E, Kobayashi K, Inoue K, Lopez LR, Shoenfeld Y: Oxidized LDL/beta2-glycoprotein I complexes: new aspects in atherosclerosis. Lupus. 2005, 14 (9): 736-741. 10.1191/0961203305lu2211oaView ArticlePubMedGoogle Scholar
- Ioannou Y, Zhang JY, Qi M, Gao L, Qi JC, Yu DM, Lau H, Sturgess AD, Vlachoyiannopoulos PG, Moutsopoulos HM: Novel assays of thrombogenic pathogenicity in the antiphospholipid syndrome based on the detection of molecular oxidative modification of the major autoantigen beta2-glycoprotein I. Arthritis Rheum. 2011, 63 (9): 2774-2782. 10.1002/art.30383PubMed CentralView ArticlePubMedGoogle Scholar
- Passam FH, Rahgozar S, Qi M, Raftery MJ, Wong JW, Tanaka K, Ioannou Y, Zhang JY, Gemmell R, Qi JC: Redox control of beta2-glycoprotein I-von Willebrand factor interaction by thioredoxin-1. J Thromb Haemost. 2010, 8 (8): 1754-1762. 10.1111/j.1538-7836.2010.03944.xPubMed CentralView ArticlePubMedGoogle Scholar
- Kockx MM, Herman AG: Apoptosis in atherosclerosis: beneficial or detrimental?. Cardiovasc Res. 2000, 45 (3): 736-746. 10.1016/S0008-6363(99)00235-7View ArticlePubMedGoogle Scholar
- Seimon T, Tabas I: Mechanisms and consequences of macrophage apoptosis in atherosclerosis. J Lipid Res. 2009, 50 (Suppl): S382-S387.PubMed CentralPubMedGoogle Scholar
- Dhanasekaran DN, Reddy EP: JNK signaling in apoptosis. Oncogene. 2008, 27 (48): 6245-6251. 10.1038/onc.2008.301PubMed CentralView ArticlePubMedGoogle Scholar
- Kralova J, Dvorak M, Koc M, Kral V: p38 MAPK plays an essential role in apoptosis induced by photoactivation of a novel ethylene glycol porphyrin derivative. Oncogene. 2008, 27 (21): 3010-3020. 10.1038/sj.onc.1210960View ArticlePubMedGoogle Scholar
- Kurokawa M, Kornbluth S: Caspases and kinases in a death grip. Cell. 2009, 138 (5): 838-854. 10.1016/j.cell.2009.08.021PubMed CentralView ArticlePubMedGoogle Scholar
- Palmgren JJ, Toyras A, Mauriala T, Monkkonen J, Auriola S: Quantitative determination of cholesterol, sitosterol, and sitostanol in cultured Caco-2 cells by liquid chromatography-atmospheric pressure chemical ionization mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2005, 821 (2): 144-152. 10.1016/j.jchromb.2005.04.029View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.